BioTime CEO Dr. Michael West to Present at the Jefferies 2012 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--May 30, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that its Chief Executive Officer, Michael D. West, Ph.D., will provide a corporate update at the Jefferies 2012 Global Healthcare Conference in New York City on Monday, June 4, 2012 at 3:30 p.m. ET.
The presentation will be webcast and may be accessed at http://wsw.com/webcast/jeff68/btx/ or under "Investor Presentations" on BioTime's website at www.biotimeinc.com. The webcast can be viewed live and will be available for replay for 90 days after the presentation.
The annual investor conference hosted by Jefferies will be held June 4-7 and will highlight over 300 leading public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of applications.
BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate(TM) cell lines, HyStem(R) hydrogels, culture media, and differentiation kits. BioTime is developing Renevia(TM) (formerly known as HyStem(R)-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need.
BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries.
Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards(R): the leading human gene database, and is developing an integrated database suite to complement GeneCards(R) that will also include the LifeMap(TM) database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend(R), is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime and its subsidiaries can be found at www.biotimeinc.com.
Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts CONTACT: BioTime, Inc.
Peter Garcia, 510-521-3390 ext. 367 Chief Financial Officer email@example.com or Judith Segall, 510-521-3390 ext. 301 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH SOURCE: BioTime, Inc.
Copyright Business Wire 2012 PUB: 05/30/2012 08:45 AM/DISC: 05/30/2012 08:45 AM http://www.businesswire.com/news/home/20120530005779/